While not specifically mentioned by the authors, another consideration is HER2 (ERBB2) expression in the myocardium and myoendothelium, a known factor in anti-Her2 trastuzumab cardiac toxicity.47,48 CRS is a side effect of immunotherapy that causes widespread activation of the immune system. Here, ERBB2 is linked to congenital rubella syndrome.